BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Completed · Phase 2
Conditions studied: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
In brief
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).
Key facts
- Study ID
- NCT01156311
- Run by
- Biogen
- People needed
- 108
- Starts
- 2010-06-01
- Expected to finish
- 2012-03-01
- Last updated by the study team
- 2017-03-21
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Gilbert, Arizona, United States
- Research Site — Phoenix, Arizona, United States
- Research Site — Danbury, Connecticut, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Fort Wayne, Indiana, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Golden Valley, Minnesota, United States
- Research Site — Teaneck, New Jersey, United States
- Research Site — Patchogue, New York, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Dayton, Ohio, United States
- Research Site — Portland, Oregon, United States
- Research Site — Cordova, Tennessee, United States
- Research Site — Franklin, Tennessee, United States
- Research Site — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.